Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Reference Materials RMs and Certified Reference Materials CRMs are dispatched directly to the end-user in accordance with ISO requirements. Please check regulation status before ordering; additionel fees can apply.
- Synonyms
- 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide
- Correlated keywords
- JWHs JWH018 JWH-018 JWH18 JWH 18 JWH-18 cannabinoids CBs cannabimimetics CB1 CB2 receptors agonists spices forensics science neuroscience synthetic central peripheral herbal blends analogs 1-pentyl-3-(1-adamantylamido)indole analytical references standards SDB001 SDB 001 ISO00119 ISO 119 ISO 119 ISO 00119
- Product Overview:
JWH 018 is a synthetic cannabinoid (CB) which potently activates both the central CB1 and peripheral CB2 receptors (Ki = 9.0 and 2.94 nM, respectively).{16797} This cannabimimetic compound has frequently been found in herbal blends.{18620,18621,18618} Structurally, JWH 018 is an alkylindole joined to a naphthyl group by methanone. JWH 018 adamantyl carboxamide is a structural analog of JWH 018 where the naphthalenyl-methanone portion has been replaced by adamantyl carboxamide. While the physiological properties of this compound are not known, quinolones with adamantyl carboxamide moieties display high affinity for the CB2 receptor but greatly reduced affinity for the CB1 receptor. This product is intended for research and forensic applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.